Immunotherapy with or without liver artery chemo for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with liver cancer that is advanced or has spread within the liver.
- Your cancer has not been treated with systemic therapy or liver artery chemo before.
- You have good liver function (Child-Pugh A) and are in fair general health (ECOG 0-1).
- You have at least one tumor that can be measured by scan, and your blood counts and kidney function are within certain limits.
- You agree to use effective birth control if needed, and you do not have active hepatitis, HIV, or other serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This Phase 2 trial studies whether delivering an immunotherapy drug directly into the liver’s artery, together with bevacizumab, can shrink advanced hepatocellular carcinoma. You may be considered if prior whole-body (systemic) treatment has not worked and prior local procedures were also not tolerated or failed.
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.